Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | PRNP | P04156 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CAMK2D | Q13557 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | RXRA | P19793 | 2/20 | 0.47 |
| ▸ | RXRB | P28702 | 2/20 | 0.47 |
| ▸ | KMO | O15229 | 2/20 | 0.47 |
| ▸ | RXRG | P48443 | 1/20 | 0.47 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.45 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | SMO | Q99835 | 2/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4900078 | 1.00 | MAP4K4 (0.54) | MAP4K4MEN1KMT2AKDM4EPRNP | |
| SCHEMBL4894262 | 0.85 | CAMK2D (0.50) | CAMK2DRXRARXRBKMORXRG | |
| SCHEMBL4898606 | 0.83 | MAP4K4 (0.75) | MAP4K4MEN1KMT2AKDM4EPRNP | |
| SCHEMBL4901594 | 0.83 | MEN1 (0.69) | MAP4K4MEN1KMT2AKDM4EPRNP | |
| SCHEMBL4897772 | 0.83 | MEN1 (0.69) | MAP4K4MEN1KMT2AKDM4EPRNP | |
| SCHEMBL4899395 | 0.83 | CAMK2D (0.64) | MAP4K4MEN1KMT2AKDM4EPRNP | |
| SCHEMBL31301500 | 0.82 | KMO (0.69) | KMO | |
| SCHEMBL4900944 | 0.81 | CAMK2D (0.62) | MAP4K4MEN1KMT2AKDM4EPRNP | |
| SCHEMBL4889753 | 0.81 | MAP4K4 (0.47) | MAP4K4MEN1KMT2AKDM4EPRNP | |
| SCHEMBL27687559 | 0.80 | RXRA (0.49) | MEN1KMT2AMAPTRXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160229818-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | PTC THERAPEUTICS, INC. (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160229818-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | PTC THERAPEUTICS, INC. (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160229818-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | PTC THERAPEUTICS, INC. (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC THERAPEUTICS, INC. | 2016-07-14 | — | — | US | disclosed |
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC THERAPEUTICS, INC. | 2016-07-14 | — | — | US | disclosed |
| US-9315467-B2 | Compounds for nonsense suppression, and methods for their use | PTC THERAPEUTICS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9315467-B2 | Compounds for nonsense suppression, and methods for their use | PTC THERAPEUTICS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9315467-B2 | Compounds for nonsense suppression, and methods for their use | PTC THERAPEUTICS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9289398-B2 | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | PTC THERAPEUTICS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9289398-B2 | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | PTC THERAPEUTICS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| EP-2387995-A1 | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | PTC Therapeutics, Inc. (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20110046136-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH | THERAPEUTICS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046136-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH | THERAPEUTICS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20080119473-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | PTC THERAPEUTICS, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119473-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | PTC THERAPEUTICS, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119473-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | PTC THERAPEUTICS, INC. | 2008-05-22 | — | — | US | disclosed |
| WO-2007117438-A2 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC THERAPEUTICS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| EP-1799212-A2 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC Therapeutics, Inc. (US) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006044505-A2 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC THERAPEUTICS, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046136-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH | UPF1, DNAJC10, RNGTT | MAP4K4 3519/4885MEN1 3100/4885KMT2A 2713/4885 |
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | UPF1, DNAJC10, RNGTT | MAP4K4 3653/4885MEN1 2786/4885KMT2A 2626/4885 |
| US-20080119473-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | NSUN2, UPF1, NSUN3 | MAP4K4 4159/4885MEN1 2836/4885KMT2A 1404/4885 |
| US-20160229818-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | NSUN2, UPF1, NSUN3 | MAP4K4 4159/4885MEN1 2836/4885KMT2A 1404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.